Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josefa Ruiz-Morales

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Medicina Clinica|May 30, 2018
Left endocarditis, changes in the new millenniumMariam Noureddine-López, Javier de la Torre-Lima, Josefa Ruiz-Morales, et al.
The Journal of Antimicrobial Chemotherapy|September 8, 2006
Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimenLuis F Lopez-Cortes, Rosa Ruiz-Valderas, Josefa Ruiz-Morales, et al.
Revista Espanola De Cardiologia (English Ed.)|April 30, 2014
Influence of a multidisciplinary alert strategy on mortality due to left-sided infective endocarditisFernando Carrasco-Chinchilla, Gemma Sánchez-Espín, Josefa Ruiz-Morales, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 24, 2009
Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patientsJuan A Pineda, Manuela Aguilar-Guisado, Antonio Rivero, et al.
Journal of Hepatology|February 24, 2009
Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patientsNicolás Merchante, Ignacio de los Santos-Gil, Dolores Merino, et al.
AIDS (London, England)|December 6, 2005
Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver diseaseNicolás Merchante, José A Girón-González, Mercedes González-Serrano, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 12, 2015
Incidence and clinical impact of infective endocarditis after transcatheter aortic valve implantationManuel Martínez-Sellés, Emilio Bouza, Pablo Díez-Villanueva, et al.
The Journal of Antimicrobial Chemotherapy|September 10, 2011
Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patientsKarin Neukam, José A Mira, Josefa Ruiz-Morales, et al.
Plos One|February 6, 2016
Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP CohortKarin Neukam, José A Mira, Antonio Collado, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|May 30, 2009
[Enterococcal endocarditis: a multicenter study of 76 cases]Francisco Javier Martínez-Marcos, José Manuel Lomas-Cabezas, Carmen Hidalgo-Tenorio, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Medicina Clinica|May 30, 2018
Left endocarditis, changes in the new millenniumMariam Noureddine-López, Javier de la Torre-Lima, Josefa Ruiz-Morales, et al.
The Journal of Antimicrobial Chemotherapy|September 8, 2006
Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimenLuis F Lopez-Cortes, Rosa Ruiz-Valderas, Josefa Ruiz-Morales, et al.
Revista Espanola De Cardiologia (English Ed.)|April 30, 2014
Influence of a multidisciplinary alert strategy on mortality due to left-sided infective endocarditisFernando Carrasco-Chinchilla, Gemma Sánchez-Espín, Josefa Ruiz-Morales, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 24, 2009
Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patientsJuan A Pineda, Manuela Aguilar-Guisado, Antonio Rivero, et al.
Journal of Hepatology|February 24, 2009
Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patientsNicolás Merchante, Ignacio de los Santos-Gil, Dolores Merino, et al.
AIDS (London, England)|December 6, 2005
Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver diseaseNicolás Merchante, José A Girón-González, Mercedes González-Serrano, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 12, 2015
Incidence and clinical impact of infective endocarditis after transcatheter aortic valve implantationManuel Martínez-Sellés, Emilio Bouza, Pablo Díez-Villanueva, et al.
The Journal of Antimicrobial Chemotherapy|September 10, 2011
Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patientsKarin Neukam, José A Mira, Josefa Ruiz-Morales, et al.
Plos One|February 6, 2016
Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP CohortKarin Neukam, José A Mira, Antonio Collado, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|May 30, 2009
[Enterococcal endocarditis: a multicenter study of 76 cases]Francisco Javier Martínez-Marcos, José Manuel Lomas-Cabezas, Carmen Hidalgo-Tenorio, et al.
Pageof 2